Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
ET (Essential Thrombocythemia): early-phase trial registry
1 of 2 indexed ET (Essential Thrombocythemia) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
ET (Essential Thrombocythemia): 2 US clinical trials tracked, 1 recruiting.
ET (Essential Thrombocythemia) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is MPN Research Foundation, running 1 of these trials.
Enrollment posture brief
Registry condition et-essential-thrombocythemia
OPEN 1 | RECR 50% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
ET (Essential Thrombocythemia) lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for ET (Essential Thrombocythemia) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
ET (Essential Thrombocythemia) is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
MPN Research Foundation
NCT07362225
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Incyte Corporation
NCT04279847
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on ET (Essential Thrombocythemia) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on ET (Essential Thrombocythemia) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this ET (Essential Thrombocythemia) page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 ET (Essential Thrombocythemia) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- MPN Research Foundation sponsors the most ET (Essential Thrombocythemia) trials on record, review their full trial history before evaluating a specific study. See MPN Research Foundation's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This ET (Essential Thrombocythemia) condition card totals 2 registered trials; most-linked intervention INCB057643; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.